home / stock / txmd / txmd quote
Last: | $1.78 |
---|---|
Change Percent: | -2.17% |
Open: | $1.88 |
Close: | $1.78 |
High: | $1.88 |
Low: | $1.75 |
Volume: | 16,796 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.78 | $1.88 | $1.78 | $1.88 | $1.75 | 16,796 | 07-22-2024 |
$1.84 | $1.81 | $1.84 | $1.88 | $1.81 | 6,836 | 07-19-2024 |
$1.81 | $1.77 | $1.81 | $1.89 | $1.77 | 5,162 | 07-18-2024 |
$1.801 | $1.85 | $1.801 | $1.9 | $1.771 | 9,859 | 07-17-2024 |
$1.87 | $1.85 | $1.87 | $1.9053 | $1.82 | 7,967 | 07-16-2024 |
$1.83 | $1.85 | $1.83 | $1.85 | $1.8 | 12,755 | 07-15-2024 |
$1.85 | $1.83 | $1.85 | $1.87 | $1.79 | 32,524 | 07-12-2024 |
$1.78 | $1.77 | $1.78 | $1.83 | $1.7088 | 12,067 | 07-11-2024 |
$1.75 | $1.81 | $1.75 | $1.81 | $1.6969 | 8,889 | 07-10-2024 |
$1.78 | $1.79 | $1.78 | $1.8411 | $1.755 | 27,135 | 07-09-2024 |
$1.7003 | $1.5 | $1.7003 | $1.73 | $1.4769 | 33,411 | 07-08-2024 |
$1.51 | $1.57 | $1.51 | $1.57 | $1.4302 | 50,942 | 07-05-2024 |
$1.57 | $1.65 | $1.57 | $1.745 | $1.57 | 10,542 | 07-04-2024 |
$1.57 | $1.65 | $1.57 | $1.745 | $1.57 | 10,542 | 07-03-2024 |
$1.66 | $1.71 | $1.66 | $1.75 | $1.65 | 33,884 | 07-02-2024 |
$1.71 | $1.69 | $1.71 | $1.8232 | $1.66 | 26,150 | 07-01-2024 |
$1.61 | $1.75 | $1.61 | $1.83 | $1.61 | 37,799 | 06-28-2024 |
$1.74 | $1.71 | $1.74 | $1.84 | $1.67 | 62,506 | 06-27-2024 |
$1.72 | $1.82 | $1.72 | $1.8615 | $1.72 | 12,369 | 06-26-2024 |
$1.81 | $1.81 | $1.81 | $1.87 | $1.81 | 8,222 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...